Placental growth factor upregulation is a host response to antiangiogenic therapy

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 976-988

  Bagley, Rebecca G ^a   Ren, Yi ^a   Weber, William ^a   Yao, Min ^a   Kurtzberg, Leslie ^a   Pinckney, Jason ^a   Bangari, Dinesh ^a   Nguyen, Cokey ^a   Brondyk, William ^a   Kaplan, Johanne ^a   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; PLACENTAL GROWTH FACTOR; RECOMBINANT PROTEIN FLT01; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; RECOMBINANT FUSION PROTEINS; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79952271819     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2687     Document Type: Article

References (53)

1. Staton CA, Brown NJ, Reed MWR. Current status and future prospects for anti-angiogenic therapies in cancer. Exp Opin Drug Discov 2009;4:961-79.
2. Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 1996;271:3154-62.
3. Maglione D, Guierriero V, Viglietto G, Delli-Bovi P, Persico M. Isolation of a human placenta cDNA coding for a protein relation to the vascular permeability factor. Proc Natl Aacd Sci U S A 1991;88:9267-71. (Pubitemid 21915612)
4. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8. (Pubitemid 28399784)
5. Park JE, Chen HH, Winder J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54.
6. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002;115:2559-67. (Pubitemid 34778073)
7. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83. (Pubitemid 32448325)
8. Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 2010;70:6537-47.
9. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 2001;61:2696-703. (Pubitemid 32685857)
10. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-52. (Pubitemid 34525755)
11. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006;20:E664-73.
12. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54: 4233-7. (Pubitemid 24258135)
13. Woo IS, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, et al. Expression of placental growth factor gene in lung cancer. Tumor Biol 2004;25:1-6. (Pubitemid 38822764)
14. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of placental growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. W J Surg Oncol 2005;3:69.
15. Kodama J, Seki N, Tokumo K, Nakanishi Y, Yoshinouchi M, Kudo T. Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma. Eur J Gynaecol Oncol 1997;18:508-10. (Pubitemid 27519422)
16. Matsumoto K, Suzuki K, Koike H, Hasumi M, Matsui H, Okugi H, et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. Anticancer Res 2003;23:3767-73. (Pubitemid 37474323)
17. Graeven U, Rodeck U, Karpinski S, Jost M, Andre N, Shmiegel W. Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol 2000;115:118-23. (Pubitemid 30470202)
18. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000;115:1000-7. (Pubitemid 32037443)
19. Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 2010;23:537-44.
20. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nature 2009;6:395-404.
21. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007;6:524-31. (Pubitemid 46332454)
22. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75. (Pubitemid 350007692)
23. Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Assoc Sci U S A 2007;104:17069-74. (Pubitemid 350210993)
24. Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007;250:237-49. (Pubitemid 46529444)
25. Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105:158-64. (Pubitemid 36505315)
26. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9.
27. Willet CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multi-disciplinary phase II study. J Clin Oncol 2009;27:3020-6.
28. Michaelson MD, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20.
29. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
30. Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53.
31. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77.
32. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010; 141:178-90.
33. Bagley RG, Kurtzberg L, Weber W, Nguyen T-H, Lovewell G, Nguyen C, et al. sFLT01: a novel fusion protein with anti-angiogenic activity. Mol Cancer Ther 2010 Jan 20. [Epub ahead of print].
34. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors of inhibition of retinal neovascularization. Gene Ther 2009;16:10-6.
35. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. Inhibition of choroidal neovascularization in a non-human primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2010 Oct 26. [Epub ahead of print].
36. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005; 11:2364-78. (Pubitemid 40490198)
37. Liang W-C, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Cehm 2006;28:951-61.
38. Keck PJ, Hauser S, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989:1309-12. (Pubitemid 20066717)
39. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placental growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40. (Pubitemid 128767693)
40. Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen YF, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology. Cancer Chemother Pharmacol 2003;51:321-7. (Pubitemid 36629810)
41. Parr C, Watkins G, Boulton M, Cai J, Jiang WG. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005;41:2819-27. (Pubitemid 41713119)
42. Pompeo E, Albonici L, Doldo E, Orlandi A, Manzari V, Modesti A, et al. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 2009;88:426-31.
43. Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC, Wong JM. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009;52:1630-6.
44. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32-43.
45. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al. Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16:358-66.
46. Motzer R, Michaelson M, Redman B, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
47. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-49.
48. Marcellini M,DeLuca N, Riccioni T, Ciucci A, Orecchia A, LacalPM, et al. Increased melanoma growth and metastasis spreading in mice over-expressing placental growth factor. Am J Pathol 2006;169:643-54. (Pubitemid 44156320)
49. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-39.
50. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
51. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471-8.
52. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74. (Pubitemid 43093963)
53. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008;11:219-30.